Literature DB >> 12072369

Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster.

Martha Triantafilou1, Kathy Triantafilou.   

Abstract

Recognition of bacterial lipopolysaccharide (LPS) by the innate immune system elicits strong pro-inflammatory responses that can eventually cause a fatal sepsis syndrome in humans. LPS-mediated activation of mammalian cells is believed to involve the interaction of LPS with lipopolysaccharide-binding protein (LBP) in the serum and, subsequently with CD14. Although there is no doubt that CD14 binds LPS, CD14 is not capable of initiating a transmembrane activation signal because it is a glycosylphosphatidylinositol (GPI)-anchored protein. Accumulating evidence has suggested that LPS must interact with a transmembrane receptor(s) that is responsible for signal transduction. Integrins CD11c and/or CD18, Toll-like receptors (TLRs), as well as CD55, have been suggested to serve this function. Recently, we have revealed that a signalling complex of receptors is formed following LPS stimulation, which comprises heat-shock proteins (Hsps) 70 and 90, chemokine receptor 4 (CXCR4) and growth differentiation factor 5 (GDF5). Taking into account the discovery of the TLRs and the LPS-activation cluster, we propose a new model of LPS recognition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072369     DOI: 10.1016/s1471-4906(02)02233-0

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  214 in total

1.  LBP and CD14 polymorphisms correlate with increased colorectal carcinoma risk in Han Chinese.

Authors:  Rui Chen; Fu-Kang Luo; Ya-Li Wang; Jin-Liang Tang; You-Sheng Liu
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein.

Authors:  Claire Sunyach; Angela Jen; Juelin Deng; Kathleen T Fitzgerald; Yveline Frobert; Jacques Grassi; Mary W McCaffrey; Roger Morris
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

Review 3.  Role of Toll-like receptors in pathogen recognition.

Authors:  S Janssens; R Beyaert
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

Review 4.  Eczema in early life: genetics, the skin barrier, and lessons learned from birth cohort studies.

Authors:  Jocelyn M Biagini Myers; Gurjit K Khurana Hershey
Journal:  J Pediatr       Date:  2010-08-24       Impact factor: 4.406

Review 5.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

Review 6.  Membrane TLR signaling mechanisms in the gastrointestinal tract during sepsis.

Authors:  B M Buchholz; A J Bauer
Journal:  Neurogastroenterol Motil       Date:  2010-03       Impact factor: 3.598

7.  Glycogen synthase kinase-3 negatively regulates anti-inflammatory interleukin-10 for lipopolysaccharide-induced iNOS/NO biosynthesis and RANTES production in microglial cells.

Authors:  Wei-Ching Huang; Yee-Shin Lin; Chi-Yun Wang; Cheng-Chieh Tsai; Hsiang-Chi Tseng; Chia-Ling Chen; Pei-Jung Lu; Po-See Chen; Li Qian; Jau-Shyong Hong; Chiou-Feng Lin
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

8.  beta-Arrestin 2: a Negative Regulator of Inflammatory Responses in Polymorphonuclear Leukocytes.

Authors:  Fahmin Basher; Hongkuan Fan; Basilia Zingarelli; Keith T Borg; Lou M Luttrell; George E Tempel; Perry V Halushka; James A Cook
Journal:  Int J Clin Exp Med       Date:  2008-01-20

Review 9.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

10.  Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.

Authors:  Jonah R Riddell; Xiang-Yang Wang; Hans Minderman; Sandra O Gollnick
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.